Information

This site is only for use by healthcare professionals. By continuing to view this site you are confirming that you are a healthcare professional.

Confirm

Key Opinions in Medicine

  • Register
  • Login
Skip to content
  • Home
  • Issues
    • Allergy & Immunology
    • Cardiology
    • Conference
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes & Endocrinology
    • Gastroenterology
    • General Medicine
    • Haematology
    • Hepatology
    • Infectious Diseases
    • Metabolic Disorders
    • Neurology
    • Nursing
    • Obstetrics & Gynaecology
    • Oncology
    • Paediatrics
    • Psychiatry
    • Rheumatology
    • Surgery Insights
    • Urology
  • About
  • Contact
  • Register
  • Login

Issues

Ixazomib▼: a novel oral proteasome inhibitor

Ixazomib▼: a novel oral proteasome inhibitor

...

Ixazomib▼: a novel oral proteasome inhibitor

Ixazomib▼: a novel oral proteasome inhibitor

...

Ixazomib▼: a novel oral proteasome inhibitor

Ixazomib▼: a novel oral proteasome inhibitor

...

Ixazomib▼: a novel oral proteasome inhibitor

Ixazomib▼: a novel oral proteasome inhibitor

...

IL-17A-Inhibitor bei Plaque-Psoriasis

IL-17A-Inhibitor bei Plaque-Psoriasis

...

IL-17A-Inhibitor bei Plaque-Psoriasis

IL-17A-Inhibitor bei Plaque-Psoriasis

...

IL-17A-Inhibitor bei Plaque-Psoriasis

IL-17A-Inhibitor bei Plaque-Psoriasis

...

IL-17A-Inhibitor bei Plaque-Psoriasis

IL-17A-Inhibitor bei Plaque-Psoriasis

...

IL-17A-Inhibitor bei Plaque-Psoriasis

IL-17A-Inhibitor bei Plaque-Psoriasis

...

IL-17A-Inhibitor bei Plaque-Psoriasis

IL-17A-Inhibitor bei Plaque-Psoriasis

...

1 … 18 19 20 21 22 … 38

Search Issues

RSS Feeds

  • All issues

Specialties

Click below to filter the KOM articles by specialty...

  • Allergy & Immunology
  • Cardiology
  • Conference
  • Critical Care
  • Dentistry
  • Dermatology
  • Diabetes & Endocrinology
  • Gastroenterology
  • General Medicine
  • Haematology
  • Hepatology
  • Infectious Diseases
  • Metabolic Disorders
  • Neurology
  • Nursing
  • Obstetrics & Gynaecology
  • Oncology
  • Paediatrics
  • Psychiatry
  • Rheumatology
  • Surgery Insights
  • Urology

Popular Issues

Konkurrenz für den Therapiestandard

MOVICOL® (PEG3350 plus electrolytes): 20 years of evidence-based use

Register

Register

Sign up for free access to Wiley’s Key Opinions in Medicine to keep up to date with latest trends and key developments within your specialty area.

Share

Copyright © 2000-2026 by John Wiley & Sons, Inc., or related companies. All rights reserved.
Review our privacy policy. Cookie Preferences.
Web design and marketing agency Leamington Spa